APA (7th ed.) Citation

Thambi, N., Phuah, J. Y., Staupe, R. P., Tobias, L. M., Cao, Y., McKelvey, T., . . . Vora, K. A. (2025). Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150. Journal of Infectious Diseases, 231(3), e488. https://doi.org/10.1093/infdis/jiae582

Chicago Style (17th ed.) Citation

Thambi, Nithya, et al. "Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150." Journal of Infectious Diseases 231, no. 3 (2025): e488. https://doi.org/10.1093/infdis/jiae582.

MLA (9th ed.) Citation

Thambi, Nithya, et al. "Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150." Journal of Infectious Diseases, vol. 231, no. 3, 2025, p. e488, https://doi.org/10.1093/infdis/jiae582.